Inclusion of SNPsig® SARS-CoV-2 PCR genotyping portfolio in the NHS England Framework and expansion of SNPsig® product range

Paris, France and Camberley, UK – 17 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s SNPsig® SARS-CoV-2 polymerase chain reaction (PCR) genotyping portfolio has been included in the NHS England Framework for detecting Variants of Concern (VoC). Novacyt also announces the launch of two

Visit Page

Novacyt to support UNICEF with donation of one million COVID-19 tests

Donation supports testing efforts to help ensure continued access to essential services for children and their families Paris, France and Camberley, UK – 4 May 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT; “Novacyt”), an international clinical diagnostics company, will donate one million COVID-19 polymerase chain reaction (PCR) tests to UNICEF to help contain

Visit Page

Novacyt soutient UNICEF en faisant un don d’un million de tests COVID-19

Ce don permettra de soutenir les efforts de dépistage afin de garantir un accès continu aux services essentiels pour les enfants et leurs familles. Paris, France et Camberley, Royaume-Uni – 4 mai 2021 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, fera un don d’un million de tests

Visit Page